CheckMate-459 results for Opdivo don’t meet OS endpoint in hepatocellular carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. announced topline results from CheckMate-459, randomized phase III study evaluating Opdivo (nivolumab) vs. sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The U.S. Preventive Services Task Force is at risk of losing the expertise, evidence-review infrastructure, and institutional culture that has made it a model for evidence-based medicine. In July 2025, David Ransohoff, a gastroenterologist and clinical epidemiologist in the Division of Gastroenterology and Hepatology at University of North Carolina School of Medicine, noted that HHS...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login